Clinical Trial Update: Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors [EARLY_Phase 1]

View source ↗

Summary

This is an early-phase clinical trial update for LV009 injection evaluating its use in CD19-positive recurrent/refractory B-cell acute lymphoblastic leukemia; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• LV009

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: CD19+ Relapse/Refractory B-ALL | EARLY_Phase 1 | Status: NOT_YET_RECRUITING